Mesothelioma

Cediranib combined with platinum-based chemotherapy helped patients live longer than placebo.

A registered dietician discussed the importance of maintaining one’s weight while going through treatment for mesothelioma.

CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.

CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors. 

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

The Food and Drug Administration has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the front-line treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

An immunotherapy pair looks promising for those with pleural mesothelioma, which is now treated with chemotherapy.

Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.